Beam Therapeutics (BEAM) Short term Debt (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Short term Debt data on file, last reported at $5.2 million in Q1 2026.

• Short term Debt for Q1 2026 came in at $5.2 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.2 million (changed 0.0% YoY), and the FY2025 annual result was $7.7 million, down 8.33% from the prior year.
• Short term Debt eased to $5.2 million in Q1 2026 per BEAM's latest filing, from $7.7 million in the prior quarter.
• Over five years, Short term Debt peaked at $28.6 million in Q1 2022 and troughed at $3.9 million in Q2 2025.
• A 5-year average of $11.6 million and a median of $8.9 million in 2023 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2022 and 2024: Short term Debt tumbled 80.8% in 2022, then rose 7.87% in 2024.
• A 5-year view of Short term Debt shows it stood at $18.3 million in 2022, then plunged by 40.98% to $10.8 million in 2023, then retreated by 22.22% to $8.4 million in 2024, then declined by 8.33% to $7.7 million in 2025, then tumbled by 32.47% to $5.2 million in 2026.
• Business Quant data shows BEAM's Short term Debt at $5.2 million in Q1 2026, $7.7 million in Q4 2025, and $6.5 million in Q3 2025.